OptimizeRx Corporation
OPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.36 | -0.24 | -0.01 | 2.89 |
| FCF Yield | 0.84% | 1.82% | 2.40% | 0.09% |
| EV / EBITDA | 836.65 | 59.75 | -197.29 | 22.47 |
| Quality | ||||
| ROIC | -0.61% | 1.88% | -0.93% | -0.08% |
| Gross Margin | 67.20% | 63.83% | 60.85% | 68.15% |
| Cash Conversion Ratio | 4.11 | 2.98 | -1.76 | -2.51 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.36% | 19.38% | 15.20% | 13.84% |
| Free Cash Flow Growth | -29.86% | 18.61% | 4,819.23% | -95.41% |
| Safety | ||||
| Net Debt / EBITDA | -36.12 | 2.82 | -18.17 | 4.07 |
| Interest Coverage | -0.29 | 1.99 | -1.63 | 2.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 89.83 | 86.42 | 99.31 | 87.57 |